Funder
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, et al. Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19:1277–303.
2. Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn J-E, Wechsler B, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood J Am Soc Hematol. 2011;117:2778–82.
3. Nathoo N, Uhm JH, Porter AB, Hammack J, Jaeckle KA, Mrugala MM, et al. Clinical features and outcomes in primary nervous systemhistiocytic neoplasms. Blood Cancer J. 2024;14:101.
4. Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135:1929–45.
5. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–89.